Evidence map›Paper›PMID 35616870›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Regulation of Molecular Farming Products.

Penny A C Hundleby, Marc-André D'Aoust, Carolyn Finkle, Judith Atkins, Richard M Twyman

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Product safety aspects of plant molecular farming.Frontiers in bioengineering and biotechnology · 2023
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Penny A C HundlebyJohn Innes Centre, Norwich Research Park, UK.
Marc-André D'AoustMedicago R & D, Québec, QC, Canada.
Carolyn FinkleMedicago R & D, Québec, QC, Canada.
Judith AtkinsMedicago R & D, Québec, QC, Canada.
Richard M TwymanTRM Ltd, Scarborough, UK. richard@twymanrm.com.

Funding

Biotechnology and Biological Sciences Research Council BB/P013511/1
6 · The paper itself

Abstract

The regulation of molecular farming is a complex topic because plants and plant-based systems are relative newcomers among the many production platforms available for recombinant proteins. The regulations specific for different types of product (human/veterinary pharmaceuticals and medical devices, cosmetics, diagnostics, and research reagents) must therefore be overlaid with the regulations governing hitherto unfamiliar production platforms, and this must be achieved in different jurisdictions that handle genetically modified organisms (and genetically modified plants in particular) in very different ways. This chapter uses examples of different product types and production methods in three different jurisdictions (the USA, the EU, and Canada) to demonstrate some of the challenges facing the regulatory authorities.

Indexed as

Molecular FarmingVeterinary DrugsCanadaHumansPlants, Genetically ModifiedRecombinant ProteinsRecombinant ProteinsVeterinary DrugsCosmeticDiagnosticGMOGood manufacturing practiceMedical devicePharmaceuticalPlant cellsResearch reagentTransgenic plantsTransient expression

Identifiers

PMID35616870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.